AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AROVELLA THERAPEUTICS LTD

0.060

-0.001-1.64%

Volume:166.53K

Turnover:10K

Market Cap:72.53M

PE:-10.34

High:0.060

Open:0.060

Low:0.059

Close:0.061

52wk High:0.125

52wk Low:0.058

Shares:1.21B

Float Shares:895.86M

Volume Ratio:0.18

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.006

EPS(LYR):-0.006

ROE:-40.41%

ROA:-26.35%

PB:5.12

PE(LYR):-10.34

Loading ...

Overview Company News Filings

Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

THOMSON REUTERS

Charles River Laboratories International Inc: to Perform Viral Safety Release Testing on Clinical Batches of Ala-101

THOMSON REUTERS

Charles River to Provide GMP NGS Testing Services to Arovella Therapeutics Under New Collaboration

Arovella Therapeutics Secures Ethics Approval for First-in-Human Study of Blood Cancer Drug Candidate

MT Newswires Live

Arovella Therapeutics Ltd-Turtle to Clinical Advisory Board&Fiorenza Lead Investigator

THOMSON REUTERS

BRIEF-Arovella Therapeutics Appoints Acting CEO

Arovella Therapeutics Appoints Acting CEO; Shares Up 4%

MT Newswires Live

Arovella Therapeutics Ltd - Appoints DR Nicole Van Der Weerden as Acting CEO

THOMSON REUTERS

Arovella Therapeutics Ltd - DR Michael Baker Resigns as CEO, Board Terminates Employment

THOMSON REUTERS

BRIEF-Arovella Therapeutics Says Michael Baker Resigns As CEO

Arovella Therapeutics Ltd - Appoints David Williams as Chairman of the Board

THOMSON REUTERS

Arovella Therapeutics Ltd - DR Michael Baker Resigns as CEO and Managing Director

THOMSON REUTERS

Arovella Therapeutics Ltd-Appointment of 4X Non-Executive Directors

THOMSON REUTERS

Arovella Therapeutics Says Shareholder Notice Calling for Director Appointments is Invalid

MT Newswires Live

Arovella Therapeutics Ltd-Update Regarding Section 249D Notice

THOMSON REUTERS

April 2026's Promising Penny Stocks On The ASX

Simply Wall St.

Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay

MT Newswires Live

Arovella Therapeutics Interim Chair Retires; Shares Up 4%

MT Newswires Live

Arovella Therapeutics - Elizabeth Stoner Will Be Retiring as Interim Chair

THOMSON REUTERS

Arovella Therapeutics Ltd-Board Changes

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/ALA.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","market":"AU","secType":"STK","nameCN":"AROVELLA THERAPEUTICS LTD","latestPrice":0.06,"timestamp":1788156720000,"preClose":0.061,"halted":0,"volume":166531,"delay":0,"changeRate":-0.016393442622950834,"nameEN":"AROVELLA THERAPEUTICS LTD","floatShares":895858885,"shares":1208783672,"eps":-0.0058,"marketStatus":"Closed","change":-0.001,"latestTime":"08-31 16:12:00 AEST","open":0.06,"high":0.06,"low":0.059,"amount":9923,"amplitude":0.016393,"askPrice":0.06,"askSize":1742,"bidPrice":0.059,"bidSize":209694,"shortable":3,"etf":0,"ttmEps":-0.0058,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.061,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":0.182641,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ALA.AU","preClose":0.061,"auctionPrice":0.06,"auctionVolume":6902,"auction":3,"marketStatus":"盘后竞价","timestamp":1787896828918}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","floatShares":895858885,"roa":"-26.35%","roe":"-40.41%","lyrEps":-0.0058,"volumeRatio":0.182641,"shares":1208783672,"dividePrice":0,"high":0.06,"amplitude":0.016393,"preClose":0.061,"low":0.059,"week52Low":0.058,"pbRate":"5.12","psRate":"20.73","week52High":0.125,"institutionHeld":0,"latestPrice":0.06,"committee":0.983522,"eps":-0.0058,"divideRate":0,"volume":166531,"delay":0,"ttmEps":-0.0058,"open":0.06,"prevYearClose":0.093,"prevWeekClose":0.061,"prevMonthClose":0.06,"prevQuarterClose":0.062,"fiveDayClose":0.065,"twentyDayClose":0.06,"sixtyDayClose":0.069},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALA.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651119902","title":"Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651119902?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:02","pubTimestamp":1783944143,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BFMHRM44.USD","LU1815336091.USD","LU0390134368.USD","LU0029874061.USD","BK7096","LU0128526141.USD","BK4121","BK4585","BK4530","ALA.AU","CRL","LU0757428866.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119191","title":"Charles River Laboratories International Inc: to Perform Viral Safety Release Testing on Clinical Batches of Ala-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119191","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651119191?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:02","pubTimestamp":1783944143,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0CD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK4121","BK4530","BK4585","LU0029874061.USD","CRL","ALA.AU","LU1815336091.USD","LU0390134368.USD","LU0757428866.USD","IE00BFMHRM44.USD","BK4588","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651211993","title":"Charles River to Provide GMP NGS Testing Services to Arovella Therapeutics Under New Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2651211993","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651211993?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:01","pubTimestamp":1783944066,"startTime":"0","endTime":"0","summary":"Charles River to provide GMP NGS testing services to Arovella Therapeutics under new collaborationCharles River entered a collaboration with Arovella Therapeutics to provide GMP next-generation sequen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL4DdDks:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK4121","LU0390134368.USD","CRL","LU0757428866.USD","BK4585","LU1815336091.USD","ALA.AU","LU0128526141.USD","LU0029874061.USD","IE00BFMHRM44.USD","BK4588","BK4530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646825419","title":"Arovella Therapeutics Secures Ethics Approval for First-in-Human Study of Blood Cancer Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2646825419","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646825419?lang=en_us&edition=fundamental","pubTime":"2026-06-25 11:31","pubTimestamp":1782358272,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  received ethics approval from The Alfred and Bellberry Human Research Ethics Committees to begin its phase 1 first-in-human clinical trial of ALA-101 drug candidate, a chimeric antigen receptor invariant natural killer T  cell therapy for patients with relapsed or refractory lymphomas and leukemias, according to a Thursday Australian bourse filing.The trial is expected to involve up to seven clinical sites across Australia and New Zealand, the filing said. It will evaluate the safety, tolerability, and preliminary anti-tumor activity of ALA-101.The company remains on track to begin first patient dosing in the September quarter.Arovella Therapeutics' shares fell past 1% in recent trading on Thursday and earlier hit their lowest since September 2023.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4539","ALA.AU","BK4007","BK4139","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642845916","title":"Arovella Therapeutics Ltd-Turtle to Clinical Advisory Board&Fiorenza Lead Investigator","url":"https://stock-news.laohu8.com/highlight/detail?id=2642845916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642845916?lang=en_us&edition=fundamental","pubTime":"2026-06-09 12:01","pubTimestamp":1780977683,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUE2XV1TJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633416250","title":"BRIEF-Arovella Therapeutics Appoints Acting CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2633416250","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633416250?lang=en_us&edition=fundamental","pubTime":"2026-05-07 09:25","pubTimestamp":1778117130,"startTime":"0","endTime":"0","summary":"BRIEF-Arovella Therapeutics Appoints Acting CEOMay 7  - Arovella Therapeutics Ltd ALA.AX:AROVELLA APPOINTS ACTING CEOAPPOINTS DR NICOLE VAN DER WEERDEN AS ACTING CEODR MICHAEL BAKER RESIGNS AS CEO, BOARD TERMINATES EMPLOYMENTFurther company coverage: ALA.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUE3VY61R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALA.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633161773","title":"Arovella Therapeutics Appoints Acting CEO; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633161773","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633161773?lang=en_us&edition=fundamental","pubTime":"2026-05-07 08:44","pubTimestamp":1778114678,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  appointed Nicole Van Der Weerden as acting chief executive, effective Thursday, succeeding Michael Baker, according to a same-day Australian bourse filing.The company will update the market on the CEO search process in due course, the filing added.The company's shares rose 4% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK4139","BK4007","LENZ","ALA.AU","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633165349","title":"Arovella Therapeutics Ltd - Appoints DR Nicole Van Der Weerden as Acting CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2633165349","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633165349?lang=en_us&edition=fundamental","pubTime":"2026-05-07 06:25","pubTimestamp":1778106300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nTUE3VY61R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALA.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633165314","title":"Arovella Therapeutics Ltd - DR Michael Baker Resigns as CEO, Board Terminates Employment","url":"https://stock-news.laohu8.com/highlight/detail?id=2633165314","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633165314?lang=en_us&edition=fundamental","pubTime":"2026-05-07 06:25","pubTimestamp":1778106300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nTUE3VY61R:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALA.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632814019","title":"BRIEF-Arovella Therapeutics Says Michael Baker Resigns As CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2632814019","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632814019?lang=en_us&edition=fundamental","pubTime":"2026-05-04 09:03","pubTimestamp":1777856620,"startTime":"0","endTime":"0","summary":"BRIEF-Arovella Therapeutics Says Michael Baker Resigns As CEOMay 4  - Arovella Therapeutics Ltd ALA.AX:BOARD REFRESH AND CEO RESIGNATIONDR MICHAEL BAKER RESIGNS AS CEO AND MANAGING DIRECTORAPPOINTS DAVID WILLIAMS AS CHAIRMAN OF THE BOARDFurther company coverage: ALA.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUEB7RLZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ALA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632989235","title":"Arovella Therapeutics Ltd - Appoints David Williams as Chairman of the Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2632989235","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632989235?lang=en_us&edition=fundamental","pubTime":"2026-05-04 08:00","pubTimestamp":1777852831,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUEB7RLZG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALA.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632236989","title":"Arovella Therapeutics Ltd - DR Michael Baker Resigns as CEO and Managing Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2632236989","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632236989?lang=en_us&edition=fundamental","pubTime":"2026-05-04 08:00","pubTimestamp":1777852831,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUEB7RLZG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630321285","title":"Arovella Therapeutics Ltd-Appointment of 4X Non-Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2630321285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630321285?lang=en_us&edition=fundamental","pubTime":"2026-04-28 13:58","pubTimestamp":1777355927,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUE8BNGHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALA.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629095835","title":"Arovella Therapeutics Says Shareholder Notice Calling for Director Appointments is Invalid","url":"https://stock-news.laohu8.com/highlight/detail?id=2629095835","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629095835?lang=en_us&edition=fundamental","pubTime":"2026-04-22 11:24","pubTimestamp":1776828296,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  said a recent notice from shareholder The Trust Company  calling for a general meeting to appoint three directors is considered invalid, according to a Wednesday filing with the Australian bourse.The company disclosed the notice on April 10, saying the shareholder holds more than 5% of voting shares.Arovella Therapeutics said the notice \"cannot be lawfully effected at a general meeting,\" and it has invited the shareholder to formally withdraw the invalid notice.It added that its board has sought to meet with the director nominees, but its requests were declined.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALA.AU","BK4539","BK4007","LENZ","BK7096","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629062203","title":"Arovella Therapeutics Ltd-Update Regarding Section 249D Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2629062203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629062203?lang=en_us&edition=fundamental","pubTime":"2026-04-22 09:05","pubTimestamp":1776819959,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUE3YPCMG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627096851","title":"April 2026's Promising Penny Stocks On The ASX","url":"https://stock-news.laohu8.com/highlight/detail?id=2627096851","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627096851?lang=en_us&edition=fundamental","pubTime":"2026-04-13 03:02","pubTimestamp":1776020520,"startTime":"0","endTime":"0","summary":"Australian shares are entering the weekend on a steady note, with investors showing patience amid ongoing geopolitical discussions and national energy security measures. In this context, penny stocks—though often considered a term from past trading days—still represent viable opportunities for growth. These smaller or newer companies can offer significant potential when backed by strong financials, and this article explores three such promising stocks on the ASX that may present hidden value...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice2-main-header/1585186777117","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice2-main-header/1585186777117"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-cvl/civmec-shares/news/april-2026s-promising-penny-stocks-on-the-asx","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-cvl/civmec-shares/news/april-2026s-promising-penny-stocks-on-the-asx","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LBL.AU","CLX.AU","BK7055","BK7062","OBM.AU","BK7084","RPL.AU","ALA.AU","BK7047","FEX.AU","IRI.AU","BK7016","SPZ.AU","BK7503","BK7058","CGS.AU","BK7088","BK7132","BK7094","CVL.AU","WAF.AU","BK7104","BK7096","EDU.AU","BK7129","PPS.AU","BK7506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624636785","title":"Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay","url":"https://stock-news.laohu8.com/highlight/detail?id=2624636785","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624636785?lang=en_us&edition=fundamental","pubTime":"2026-04-01 10:42","pubTimestamp":1775011349,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor , which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancercells when incorporated into invariant natural killer T  cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.The company's shares rose nearly 3% in recent trading on Wednesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CAR.AU","BK7096","BK4022","BK7503","BK4007","CAR","BK7002","LENZ","BK4139","ALA.AU","BK4539","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610916505","title":"Arovella Therapeutics Interim Chair Retires; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610916505","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610916505?lang=en_us&edition=fundamental","pubTime":"2026-02-09 07:58","pubTimestamp":1770595091,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  said that interim Chair Elizabeth Stoner has retired, effective Monday, according to a same-day Australian bourse filing.The company will provide updates regarding the appointment of a new chair following the completion of a skills review, the filing added.The company's shares rose 4% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK4139","BK4007","LENZ","ALA.AU","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610950311","title":"Arovella Therapeutics - Elizabeth Stoner Will Be Retiring as Interim Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2610950311","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610950311?lang=en_us&edition=fundamental","pubTime":"2026-02-09 07:00","pubTimestamp":1770591641,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nTUEB9CV11:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALA.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610161503","title":"Arovella Therapeutics Ltd-Board Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2610161503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610161503?lang=en_us&edition=fundamental","pubTime":"2026-02-09 07:00","pubTimestamp":1770591641,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nTUEB9CV11:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}